Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Galapagos NV (GLPG)

Amsterdam
Currency in EUR
Disclaimer
27.56
+0.22(+0.80%)
Closed

GLPG Comments

small volume.
Such random bs. While everything is green, this is red
https://www.ema.europa.eu/en/medicines/human/summaries-opinion/jyseleca On 23 July 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Jyseleca, intended for the treatment of rheumatoid arthritis. The applicant for this medicinal product is Gilead Sciences Ireland UC. Jyseleca will be available as 100 mg and 200 mg film-coated tablets. The active substance of Jyseleca is filgotinib, an immunosuppressants (ATC code: L04AA45). Filgotinib is an adenosine triphosphate (ATP) competitive and reversible inhibitor of the Janus kinase (JAK) family.
Strong BUY now
5 min press release
Finaly a drug that works "Remdesivir", congratilations Galapagos and Gilead!!
Investor overreaction though. Besides, the main application of Filgotinib is not for ulcerative colitis (turnover approximately EUR 500 million) but for rheumatism (turnover EUR 5 BILLION). Great starting moment now.
a little dip below 200 today
just a matter of time before the gap from 15/07 will get closed.
https://pharmaphorum.com/news/gilead-make-move-galapagos-within-weeks/
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.